These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35261710)

  • 1. Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
    Barnes M; Calcanes G; Mosier MC; Vacirca J; Malik Z
    Am Health Drug Benefits; 2021 Sep; 14(3):1-7. PubMed ID: 35261710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
    Barnes M; Calcanes G; Mosier MC; Vacirca J; Malik Z
    Am Health Drug Benefits; 2021 Dec; 14(4):133-139. PubMed ID: 35261717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
    Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
    Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
    Vacirca J; Caruana D; Calcanes G; Mosier M; Boccia R; McBride A
    Future Oncol; 2018 Jun; 14(14):1387-1396. PubMed ID: 29421926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydration requirements in patients receiving highly emetogenic chemotherapy.
    Erickson R; Nebughr N; Mosier MC; Nibley W
    Future Oncol; 2019 Mar; 15(7):753-761. PubMed ID: 30499739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Deeks ED
    Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.
    Schwartzberg LS; Marks SM; Gabrail NY; Geller RB; Kish J
    J Comp Eff Res; 2019 Jul; 8(9):657-670. PubMed ID: 31070042
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.
    Boccia R; Cooper W; O'Boyle E
    J Community Support Oncol; 2015 Feb; 13(2):38-46. PubMed ID: 25866983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron.
    Ottoboni T; Gelder MS; O'Boyle E
    J Exp Pharmacol; 2014; 6():15-21. PubMed ID: 27186139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron: in the prevention of nausea and vomiting.
    Yang LP; Scott LJ
    Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
    Araz M; Karaagac M; Korkmaz L; Koral L; Inci F; Beypinar I; Uysal M; Artac M
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1091-1097. PubMed ID: 30963213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study.
    Miyoshi T; Miyashita H; Matsuo N; Odawara M; Hori M; Hiraki Y; Kawanaka H
    Biol Pharm Bull; 2021; 44(10):1413-1418. PubMed ID: 34602550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
    Gamble M; Carroll E; Wright GC; Glode AE
    J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.